Nottingham pharma firm makes £500,000 investment

Nottingham-based Upperton Pharma Solutions has made a £500,000 investment in new equipment that it says will “significantly” expand its tablet manufacturing capabilities.

The firm has bought tablet processing equipment for wet granulation, roller compaction, tablet compression, hardness testing, dedusting, weight sorting and tablet coating.

Paul Kelsall, director of clinical manufacture said: “This suite of equipment has considerably expanded Upperton’s capabilities and scale with respect to tablets. It has enabled us to recently onboard a number of new tablet dosage form projects and provides us with enhanced capabilities to offer our clients a wide range of tablet processing options. We now have the tools to offer tablet as a dosage form to support client projects from early material characterisation, design of experiments concepts, first in human studies through to phase II clinical manufacture and technical transfer support.”

Upperton Pharma Solutions develops and produces oral and inhalation drug products for clinical trials.

Dr Richard Johnson, founder and chief executive added: “This significant package of investment signals our commitment to continued growth and expansion of our services in order to meet the growing demands of our clients in oral solid dosage form development. It complements Upperton’s already established world class reputation for the use of spray drying as the principle enabling technology for poorly soluble compounds and ensures that we can support our client through the entire development process from early R&D to clinical supply.”